Tirzepatide is the drug your doctor can actually prescribe today. Retatrutide is the one the whole obesity-medicine world is whispering about, because in trials it pushed weight loss past a line nobody thought a single injection could reach. The catch is that one of these is FDA approved and the other is still years away from a pharmacy counter, no matter what an Instagram vendor tells you.
Direct answer: Tirzepatide (Mounjaro, Zepbound) is an FDA-approved dual GIP/GLP-1 agonist that produced up to 22.5% body-weight loss in phase 3 trials. Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist that reached roughly 24% at 48 weeks in phase 2 and nearly 30% in early phase 3 data, but it is not yet approved anywhere.
What is the actual difference between retatrutide and tirzepatide?
Both drugs come from Eli Lilly, and both are once-weekly injectables that quiet appetite by mimicking gut hormones. The difference is how many hormone receptors they hit at once.
Tirzepatide is a dual agonist. It activates two receptors: GIP and GLP-1. That combination is what made Mounjaro (for type 2 diabetes) and Zepbound (for weight management) the most effective approved obesity drugs on the market when they launched.
Retatrutide adds a third lever: glucagon. So it is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously (NEJM phase 2 trial, 2023). The glucagon piece matters because, counterintuitively, glucagon-receptor activation can raise energy expenditure and pull fat out of the liver. The popular shorthand calling it “GLP-3” is marketing, not science. There is no third GLP hormone. It is GLP-1 plus two other receptors.
Here is the insider read most consumer articles skip: adding glucagon is not a free win. It is a balancing act. Glucagon raises blood sugar, so the GLP-1 component has to work harder to offset that. Getting the ratio right across three receptors is exactly why a triple agonist took years longer to develop than the dual one.
How much weight do people lose on retatrutide vs tirzepatide?
This is the question driving the hype, so let me give you the real numbers from the trials, not the rounded-up headlines.
Tirzepatide (SURMOUNT-1, phase 3, NEJM): In adults with obesity or overweight, average body-weight reduction over 72 weeks was 16.0% on 5 mg, 21.4% on 10 mg, and 22.5% on 15 mg, versus 2.4% on placebo. About 96% of people on the 15 mg dose lost at least 5% of their body weight (Eli Lilly / NEJM SURMOUNT-1).
Retatrutide (phase 2, NEJM): At 48 weeks, the 12 mg dose produced a mean weight reduction of 24.2%. In that group, 100% of participants lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15% (NEJM, 2023). One detail the investigators flagged: at 48 weeks the weight-loss curve had not flattened. People were still losing.
Retatrutide (phase 3, TRIUMPH program): In Lilly’s first successful pivotal readout (TRIUMPH-4, reported December 2025), the highest 12 mg dose drove average weight loss of up to 28.7%, around 71 pounds, over 68 weeks (Eli Lilly TRIUMPH press release). The larger pivotal obesity trial, TRIUMPH-1, later showed mean weight loss of 28.3% at 80 weeks on 12 mg, with the efficacy analysis reaching as high as 30.3% (AJMC, TRIUMPH-1).
A fair-minded caveat: you cannot cleanly compare a phase 2 trial to a phase 3 trial. Different patient populations, durations, and dosing schedules. The honest takeaway is directional, not a precise scoreboard. Retatrutide appears to land in a higher weight-loss tier than tirzepatide, but the gap looks more like several percentage points than the “double the results” some sites imply.
Is retatrutide safer than tirzepatide, or does it have worse side effects?
The side-effect profiles rhyme, because they share the GLP-1 backbone. Nausea, vomiting, diarrhea, and constipation dominate both, and they cluster during the dose-escalation phase before easing off.
In the retatrutide phase 2 trial, overall adverse events were reported in 73% to 94% of participants on the drug (highest at the 8 mg and 12 mg doses) versus 70% on placebo. Nausea hit 47% of the 12 mg group and vomiting 21%, mostly mild to moderate and concentrated in the first 12 weeks (NEJM).
One signal worth watching with retatrutide: a dose-dependent rise in heart rate, with the largest average increase around 6 to 7 beats per minute at the top dose, peaking near week 24 before drifting back down. Serious adverse events were uncommon and occurred at similar rates (about 4%) in the drug and placebo groups. That heart-rate bump is the kind of thing that gets scrutinized hard in phase 3, which is precisely why we wait for the full safety dataset before calling anything “safer.”
Tirzepatide carries the GLP-1 class warnings you should know if you are weighing either drug: a boxed warning for thyroid C-cell tumors (seen in rodents; human risk unconfirmed), plus risks of pancreatitis and gallbladder problems. Retatrutide will be evaluated against the same concerns as its data matures.
Can you actually get retatrutide right now?
No, not legitimately, and this is where the conversation turns from exciting to important.
Retatrutide is investigational. It is not approved by the FDA or any major regulator for any use, and a realistic earliest approval sits around 2027 to 2028, pending the full TRIUMPH program and an FDA submission (Scientific American). The only legitimate way to access pharmaceutical-grade retatrutide today is enrollment in a clinical trial.
That gap has fueled a grey market of “research peptide” retatrutide sold online with a “not for human use” disclaimer. Treat those with serious skepticism. Unlike semaglutide and tirzepatide, retatrutide never had an approved version and was never eligible for the compounding-shortage exemption, so the legal cover some vendors imply simply does not exist. The FDA issued more than 50 warning letters in September 2025 and additional letters in March 2026 targeting peptide sellers, making clear that a “research use only” label does not exempt a product sold for human injection (The Hill). Regulators have documented heavy metals, endotoxins, and incorrect peptide sequences in seized grey-market samples. There is no clinical data on outcomes from unregulated retatrutide, no dosing oversight, and no recourse if something goes wrong.
Tirzepatide, by contrast, is available now by prescription as Mounjaro and Zepbound through normal pharmacy channels with a clinician managing your dose. If you want the most effective approved option today, that is the one that exists.
If you are new to this drug class, our primer on peptides explained walks through how these hormone-mimicking molecules work and what separates a real prescription from a grey-market vial.
Retatrutide vs tirzepatide: which should you care about?
If you need help now, the question answers itself: tirzepatide is approved, supervised, and backed by published phase 3 safety data. Retatrutide is the more powerful molecule on paper and may eventually raise the ceiling for what a single weekly shot can do, but it is a future option, not a present one. The smartest move is to work with a clinician on what is approved today and keep an eye on the TRIUMPH readouts rolling out through 2026.
Frequently asked questions
Is retatrutide stronger than tirzepatide?
In trials, retatrutide produced higher average weight loss (around 24% at 48 weeks in phase 2 and near 30% in early phase 3) than tirzepatide (up to 22.5% in phase 3). But the trials differ in design, so the comparison is directional rather than exact, and retatrutide is not yet approved.
Is retatrutide FDA approved?
No. Retatrutide is investigational and in phase 3 trials. The earliest realistic FDA approval is roughly 2027 to 2028. The only legitimate access today is through a clinical trial.
What is the third hormone in retatrutide that tirzepatide does not have?
Glucagon. Tirzepatide targets GIP and GLP-1. Retatrutide adds glucagon-receptor activation, which may boost energy expenditure and reduce liver fat. There is no “GLP-3” hormone; that name is marketing shorthand.
Do retatrutide and tirzepatide have the same side effects?
Largely yes, because they share a GLP-1 backbone: nausea, vomiting, diarrhea, and constipation, mostly during dose escalation. Retatrutide also showed a dose-dependent rise in heart rate in phase 2 that is still being studied.
Is grey-market or research-peptide retatrutide safe to use?
There is no clinical evidence supporting it, no dosing oversight, and the FDA has flagged contaminants like heavy metals and endotoxins in seized samples. It is not a safe substitute for a supervised, approved medication.
Medical disclaimer: This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.
